Crossject
Needle-free auto-injector ZENEO® and emergency drug candidates for epilepsy, adrenal crisis and anaphylaxis
Highlights
- New on EvolcAdded 2026-10-28
About Crossject
Crossject is a specialty pharmaceutical company developing emergency medications delivered through ZENEO®, a pre-filled, single-use needle-free auto-injector designed for use by untrained patients or caregivers.
The company's pipeline targets epileptic seizures (ZEPIZURE®), acute adrenal insufficiency crisis and allergic shock. It is in advanced regulatory development for ZEPIZURE® in the United States. In 2022, BARDA placed a firm order worth $60 million for an initial delivery to the U.S. Strategic National Stockpile, contingent on FDA authorization.
Crossject was founded in 2001 and is headquartered in Dijon, France. It is preparing commercialization in North America, starting with ZEPIZURE®.
Product: ZENEO® needle-free, pre-filled, single-use auto-injector for emergency intramuscular drug delivery
Jobs at Crossject
More biotech & pharma companies
Ctibiotech
Human tissue and 3D cell models with drug screening and preclinical testing for pharma and cosmetics firmsNew on EvolcCure 51
Cancer target discovery platform using exceptional survivor biology for pharmaceutical and oncology research partnersYoung companyNew on EvolcCytoo
Muscle disease drug-discovery services and micropattern products for pharmaceutical, biotechnology and research organizationsNew on EvolcDBV Technologies
Develops VIASKIN epicutaneous immunotherapy patches for patients with food allergies and other immunological diseasesNew on EvolcDeeplife
AI-driven cell digital twins and multi-omics analysis for pharmaceutical drug discovery and developmentNew on EvolcDepixus
Magnetic force spectroscopy instruments for researchers studying biomolecular interactions and drug discoveryNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Elementor
- Mailchimp
- WordPress
- jQuery
